Description du projet
Intégrer la Chine dans le Consortium international pour la médecine personnalisée (IC2PerMed)
Grâce aux progrès des technologies biomédicales et numériques, la médecine personnalisée (MP) améliore les soins de santé et soutient des systèmes de santé plus efficaces et durables. En Chine, elle suscite un intérêt considérable, le gouvernement capitalisant sur son expertise en biotechnologie et en matériel informatique, et produisant des infrastructures pour soutenir des projets de bio-informatique. Transformer la MP en une opportunité pour les citoyens et les patients nécessite l’engagement des parties prenantes à l’échelle internationale pour définir des approches, des normes et des priorités communes de recherche et développement. Afin de répondre à ces défis, l’UE soutient les actions développées au sein du Consortium international pour la médecine personnalisée (ICPerMed). Le projet IC2PerMed, financé par l’UE, fournira des solutions clés pour permettre la convergence, dans le cadre d’ICPerMed, des parties prenantes européennes et chinoises vers une approche commune de la MP, impliquant les décideurs politiques et les bénéficiaires de soins de santé.
Objectif
Personalised Medicine (PM) approaches, thanks to the latest technological advances notably in the fields of biomedical and digital technologies, prove their potential to improve healthcare and underpin more efficient and sustainable health systems.
PM is at the top of the European Commission research agenda, with funding devoted to projects along the entire value chain. In China, PM is attracting massive interest, with the government capitalising on its expertise in biotechnology, computing hardware and the ability to put in place the infrastructures for supporting large bioinformatics projects.
Turning PM into an opportunity for all citizens and patients requires the engagement of all stakeholders, in order to define common research and development approaches, standards, and priorities, and to scale up the collaboration at the International level. In order to respond to these challenges, the EU supports actions developed within the International Consortium for Personalised Medicine (ICPerMed).
IC2PerMed project will provide key solutions for enabling the convergence under ICPerMed consortium of European and Chinese stakeholders towards a common approach of PM research, innovation, development and implementation involving policy makers and healthcare beneficiaries, by:
- mapping policies, programmes, standards and initiatives related to PM in Europe in China for identifying the opportunities for research collaborations;
- structuring its developments upon an ecosystem of European and Chinese experts, collaborating in Working Groups centred on ICPerMed Action plan priorities;
- setting bridges with key organisms involved in the definition and implementation of PM and healthcare systems in both economic areas, both on benefits for coordinated approaches for research and on concrete developments taking place within and along the project;
- inserting its developments in international contexts, through ICPerMed and its involvement in relevant initiatives and networks.
Champ scientifique
Programme(s)
Régime de financement
CSA - Coordination and support actionCoordinateur
20123 Milano
Italie